Usability, Safety and Efficacy of AspivixTM

Usability, Safety and Efficacy of AspivixTM, an Atraumatic Innovative Uterine Cervical Traction Device: a Pilot Phase Followed by a Comparative Study (Pilot)

Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD). Currently, the available instruments are traumatic tenacula, which could cause pain and bleeding and therefore represent an obstacle for certain patients to pursue their medical follow-up.

AspivixTM is a new device, which enables atraumatic traction of the cervix while respecting its specific semi-circular anatomic shape through a system powered by a vacuum chamber.

The aim of our pilot study is to assess the usability, safety and efficacy of the device.

Note: Study is made of 2 phases (pilot phase followed by a comparative phase). Details regarding comparative study is registered separately.

Study Overview

• Status: Completed
• Conditions: IUD Insertion
• Intervention / Treatment: Device: AspivixTM cervical vacuum tenaculum

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Vaud
    • Lausanne, Vaud, Switzerland, 1011
      • Department Women, Mother & Child, University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Participants older than 18 years
• Participants presenting at the outpatient clinic for Mirena IUD insertion.
• Participants able to provide informed consent as documented by signature with at least 24 hours of reflection time
• Good understanding of written and oral speaking used at the centre where the study will be carried out.

Exclusion Criteria:

• Participants who are contraindicated for the insertion of the IUD Mirena
• Participants under use of excessive alcohol, narcotics or benzodiazepines prior to procedure
• Participants who do not wish to be informed of a chance discovery
• Participant receiving anaesthetics prior to IUD insertion procedure
• Participants on anticoagulant medication
• Participants under use of an analgesic
• Previous cervical operation
• Severe vaginal bleeding
• Participant previously enrolled in this study
• Cervix diameter smaller than 26 mm
• Mullerian anomalies with two cervices
• Nabothian cyst
• Cervical myomas
• Cervical condylomas
• Squamous intraepithelial lesion (Cervical dysplasia)
• Cervical endometriosis
• Cervical tears
• A well exposed cervix and / or well aligned vaginal and cervical canals where no traction is required for IUD insertion
• Other cervical abnormalities (cervical polyp, cervical lesion, or irregularity) which may contraindicate or complicate IUD insertion
• Large ectopy, for which it is not possible to find a suitable location near the ectopy where native tissue is present
• Large scar tissue, for which it is not possible to find a suitable location near the scar where native tissue is present

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: AspivixTM cervical vacuum tenaculum; Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum.	Device: AspivixTM cervical vacuum tenaculum; Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usability and efficacy from the practitioner's perspective: questionnaire	The practitioner will assess the usability and efficacy of the Investigational Device using a 5 point Likert 'Usability and Efficacy Questionnaire'.	Right after the use of the device (right after the end of the procedure to insert the IUD).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of bleeding	To assess bleeding, every buffer will be weighted, and the blank weight subtracted. Weight in mg will be reported in the case report form.	During the procedure to insert the IUD which should last less than 5 minutes.
Assessment of adverse events	Safety of the procedure will be assessed by documenting adverse events (description of the adverse events, number of participants)	During the procedure to insert the IUD which should last less than 5 minutes.
Identification of new risks	Safety of the procedure will be assessed by identifying and documenting any new risk.	During the procedure to insert the IUD which should last less than 5 minutes.
Participant's reported pain: Visual Analogue Scale	Participant's reported pain will be assessed by the patient using a 100-point Visual Analogue Scale (VAS) at specific steps during IUD insertion Minimum and maximum values range from 0 to 100, the higher score being the better outcome.	Before the procedure, during speculum insertion, during AspivixTM vacuum application, during application of cervical traction, during IUD insertion, during AspivixTM release, 5 minutes after the end of the procedure
Assessment of patient's satisfaction: questionnaire	5 point Likert 'Patient Satisfaction Questionnaire' Minimal to maximal values range from 1 to 5, 1 meaning "disagree" and 5 "agree".	Right after the use of the device (right after the end of the procedure to insert the IUD).
The number of placement attempts before traction can be applied	The number of placement attempts before traction of the cervix can be applied will be recorded	During the procedure to insert the IUD which should last less than 5 minutes.
The number of spontaneous releases during traction	The number of spontaneous releases during traction of the cervix will be recorded	During the procedure to insert the IUD which should last less than 5 minutes.
Assessment of device deficiencies	Safety of the procedure will be assessed by documenting device deficiencies (description of the deficiency)	During the procedure to insert the IUD which should last less than 5 minutes.

Collaborators and Investigators

• Sponsor: Aspivix SA

Publications and helpful links

General Publications

• Legardeur H, Masiello-Fonjallaz G, Jacot-Guillarmod M, Mathevet P. Safety and Efficacy of an Atraumatic Uterine Cervical Traction Device: A Pilot Study. Front Med (Lausanne). 2021 Dec 23;8:742182. doi: 10.3389/fmed.2021.742182. eCollection 2021.

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 1, 2020
• Primary Completion (ACTUAL): December 2, 2020
• Study Completion (ACTUAL): December 2, 2020

Study Registration Dates

• First Submitted: June 15, 2020
• First Submitted That Met QC Criteria: June 18, 2020
• First Posted (ACTUAL): June 22, 2020

Study Record Updates

• Last Update Posted (ACTUAL): December 11, 2020
• Last Update Submitted That Met QC Criteria: December 10, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: Aspivix_IUD2019_Pilot

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No